About 25% of lung cancer trials registered on ClinicalTrials.gov before 2016 remain unpublished according to a recent study. This lack of publication introduces a concerning residual lack of transparency.
The researchers identified 1294 phase II or phase III clinical trials involving patients 18 or older with recruitment status listed as complete (1038 trials; 80.2%) or terminated (256 trials; 19.8%), reports Cancer Therapy Advisor. The research team uncovered that 67.6% of trials had results and 32.4% were unpublished. The researchers found that out of all completed studies 72.5% were published and 27.5% were not published.
Interestingly, compared with industry-sponsored clinical trials, those trials sponsored by the National Institutes of Health (NIH) were more than twice as likely to be published and those trials sponsored by academic institutions were 1.5 times more likely to be published.
Interestingly, clinical trials with over 500 patients enrolled were 3 times more likely to be published compared to trials with few than 100 patients enrolled.
Chul Kim, MD, MPH, Lombardi Comprehensive Cancer Center, Georgetown University